Formulation of therapeutic agents for improved permeation
AssigneeVivtex Corporation
InventorsThomas VON ERLACH, James L. WRIGHT, Edgardo RIVERA-DELGADO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for enhanced delivery of a therapeutic agent to a subject, wherein the composition comprises the therapeutic agent, at least one bile acid or salt thereof, and optionally one or more co-excipients.
Claims42
A composition comprising
- (i) a compound selected from the group consisting of:
- (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS);
- and
- (ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.
(canceled)
-10. (canceled)
-21. (canceled)
(canceled)
-37. (canceled)
(canceled)
42-44. (canceled)
-109. (canceled)
A dosage form comprising a composition comprising
- (i) a compound selected from the group consisting of:
- (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS);
- and
- (ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.
(canceled)
-124. (canceled)
A method of enhancing gastrointestinal (GI) permeability of a compound, the method comprising administering a composition comprising
- (i) a compound selected from the group consisting of:
- (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS);
- and
- (ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt.
126-127. (canceled)
-131. (canceled)
133-134. (canceled)
-150. (canceled)
A kit comprising a container comprising a composition or a dosage form comprising
- (i) a compound selected from the group consisting of:
- (A) a polypeptide having a molecular weight of about 1 kDa to about 250 kDa, (B) a nucleic acid, and (C) a class III or class IV compound according to the Biopharmaceutical Classification System (BCS):
- (ii) an amount of at least one bile acid or salt thereof at an effective concentration greater than a critical micelle concentration (CMC) of the bile salt;
- and
- (iii) a package insert comprising instructions for administering the composition for increasing bioavailability of the compound in a subject from the GI tract.
-154. (canceled)
Dependencies are inferred from the claim text.